Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Regeneron Pharmaceuticals Inc · PHARMACEUTICAL PREPARATIONS · Now $600.66
+2.1% in 3d after detection
Post-detection moves
1h
—
1d
+0.1%
3d
+2.1%
7d
-1.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS